.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Strengthening its leadership in cancer care, the Apollo Oncology Network leadership recently welcomed Dr. Harit Kumar Chaturvedi as its Chief Executive Officer and Clinical Head. This strategic appointment aims to bolster the clinical expertise and institutional direction of the hospital group. Specifically, Dr. Chaturvedi brings nearly forty years of experience in surgical oncology to the role. Furthermore, he previously served the Apollo group as a Senior Consultant between 2000 and 2004. This return marks a significant step in the network's long-term expansion strategy.
Dr. Chaturvedi is a highly distinguished surgeon with an MCh in Surgical Oncology. During his extensive career, he has managed complex cases involving head, neck, and thoracic cancers. Additionally, he specializes in robotic and minimally invasive surgical techniques. Consequently, his clinical leadership will likely enhance the technological capabilities of the network. Notably, he has held prominent roles in the Indian Society of Oncology and the Indian Association of Surgical Oncology. He also played a key role in introducing organ-specific cancer units in North India. His leadership style focuses on assembling high-performing multidisciplinary teams.
As the new CEO, Dr. Chaturvedi plans to deepen subspecialisation across the oncology ecosystem. He intends to focus on organ-specific treatment protocols and technology-driven care. Currently, patients from over 147 countries visit Apollo for cancer treatment. Therefore, the network must maintain world-class standards of excellence. He will lead a team of more than 25 specialised oncologists to achieve these goals. This approach ensures that patients receive evidence-based and personalised treatment pathways. Moreover, the focus will remain on expanding robotic surgical capabilities nationwide. By strengthening multidisciplinary care, Apollo aims to solidify its position as a global leader in oncology.
Q1: What is Dr. Harit Kumar Chaturvedi's new role at Apollo Hospitals?
Dr. Chaturvedi has been appointed as the Chief Executive Officer (CEO) and Clinical Head of the Apollo Oncology Network.
Q2: What are the primary focus areas for the network under this new leadership?
The primary focus areas include deepening subspecialisation, expanding robotic and minimally invasive surgery, and strengthening multidisciplinary care protocols across India.
Q3: What clinical qualifications does Dr. Chaturvedi hold?
He holds an MBBS, an MS in General Surgery, and an MCh in Surgical Oncology, with 38 years of clinical experience.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Dr. Harit Kumar Chaturvedi joins Apollo Hospitals as CEO of Oncology Network to drive subspecialised, technology-driven cancer care across India....
4 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
